Pronova Starts Dosing in Phase I Clinical Trial of PRC-4016

Pronova BioPharma ASA started dosing in a Phase I clinical trial of PRC-4016, a new chemical entity for the treatment of combined dyslipidemia.

To contact the editor responsible for this story: Meera Bhatia at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.